about
Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.Combination of adenoviruses expressing melanoma differentiation-associated gene-7 and chemotherapeutic agents produces enhanced cytotoxicity on esophageal carcinoma.Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma.Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma.Multi-panel assay of serum autoantibodies in colorectal cancer.Intra-abdominal chemotherapy for peritoneal metastases comes of age?Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature.Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.Diagnostic impact of high serum midkine level in patients with gastric cancerCloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studiesPrognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinomaImmunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinomaRecent standpoints on preoperative treatment of gastroenterological cancers: Who will be a real beneficiary?Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEAHigh serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancerSystematic review of case reports of Japanese esophageal neuroendocrine cell carcinoma in the Japanese literatureSerum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgeryPrognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers
P50
Q38845658-AC4E7829-761D-43F5-B08B-E415EB78FB4DQ38920000-49C94B5B-EAD5-4C0B-8435-AA343742EAD1Q39033723-EE44972F-B9C4-43CB-8A4B-7157492AC497Q48374911-E28A2671-AF77-4AA2-8976-4ADA52AA0357Q52677772-A7CC4D8F-ABDB-4A45-B53B-0BA88D45E90BQ52716965-854F812B-C590-4570-906B-7537493C9A24Q55152522-DA15ABE3-8D34-4906-9EF7-3E57EA6B4826Q55360601-198C7B4D-6C00-4CDA-BD41-088EA0962D57Q55554723-A30E6BA1-FB28-49CE-BDAC-A5DC84CAF170Q55669873-992EAE99-9C0B-4ACD-8A3F-1A6333FA7DE2Q64269099-856639FF-ADCE-4B73-8469-4ABC8DA592B3Q64375676-9FAB8F84-C882-4554-AD15-83C073C507E3Q89357973-BDF4C727-3AA9-4F59-BE12-47733B95A8D0Q90600611-D94981E9-CADF-4C1B-8FF1-E4C6BCF80F84Q91588961-7B8314C8-0B94-4DB6-9902-D357E09E79F6Q91834793-EF15DE69-F2E5-488A-997D-AC8CC75BE27EQ92180255-326C9EAD-513E-4A63-96F2-9694887F5A5DQ92434102-CD7A53BB-AFA9-4A5F-8C7E-5FB394A0FAEEQ95843709-EC9F3301-73C3-4078-B78F-E68DDABD07A7Q96111403-2AE5F3DC-1427-431F-9E25-4C3E6D39EA13
P50
description
researcher ORCID ID = 0000-0002-1990-8217
@en
name
Hideaki Shimada
@ast
Hideaki Shimada
@en
Hideaki Shimada
@es
Hideaki Shimada
@nl
type
label
Hideaki Shimada
@ast
Hideaki Shimada
@en
Hideaki Shimada
@es
Hideaki Shimada
@nl
prefLabel
Hideaki Shimada
@ast
Hideaki Shimada
@en
Hideaki Shimada
@es
Hideaki Shimada
@nl
P108
P31
P496
0000-0002-1990-8217